We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...
TD Cowen downgraded Merck &Company Inc (NYSE:MRK) to "Hold" on concerns over uncertainty surrounding Gardasil sales, a slowdown in business development, and the looming loss of exclusivity for ...
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Merck's new products have mitigated the generic competition, offsetting the recent major patent losses. In particular, Keytruda for cancer represents a key blockbuster with multi-billion-dollar ...
Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...
Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment. It could begin competing with generic versions in the U.S. market in 2028, ...
24/7 Wall St. on MSN6d
Wall Street Analysts Thought Merck Stock Had 10% Downside Risk Heading Into Earnings. That Materialized, So What's Next?Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...
Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil ...
10don MSN
Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...
Merck swung to a fourth-quarter profit as sales grew and even exceeded Wall Street’s estimates, boosted in part by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback